Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial with uTREAT® in patients with aggressive brain cancer ...
Primary central nervous system (CNS) malignancies present unique therapeutic challenges due to their complex biology, immunosuppressive microenvironment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results